We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 0.95% | 21.20 | 20.60 | 22.00 | 21.00 | 21.00 | 21.00 | 12,949 | 16:35:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 1.47M | -6.15M | -0.0830 | -2.53 | 15.57M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/7/2020 07:25 | Unfortunately the trusty steed (Yamaha 550 Virago) has given up the ghost. I miss it and will replace at some time. I invested here at 40p ish but agree re specificity, having said that it's a bit of a numbers game and it's a relatively cheap test to run and will still pick up many early that otherwise wouldn't even have the old finger test. Pugugly, CT guided biopsy is a lot more accurate these days, but still not not 100% and is an invasive, unpleasant and expensive. | waterloo01 | |
31/7/2020 07:23 | timbo003 - but far better than a false negative - Even a multi-needle biopsy often misses - like trying to hit a pip in an orange with half a dozen needles- | pugugly | |
31/7/2020 07:16 | I remember it well Waterloo and your revelation that you got around London on a motorbike (but cannot remember which one), something I would never do with either of my two iron steeds. With Oncimmune, I follow with interest, but haven't invested, I'm still not entirely convinced the specificity is up to it (hence my question in the Q&As). The last thing you need is a false positive on something like a prostate test, which then lead to an unnecessary and extremely invasive prostate exam 😨 | timbo003 | |
31/7/2020 07:02 | Cheers. Didn't know you were also into ONC. We met once Timbo at an IMM AGM. I was the one asking most of the questions. | waterloo01 | |
31/7/2020 06:59 | They gave investors a heads up on this news at last night's Proactiveinvestor presentation, there were a couple of good Q&As at the end 😉 | timbo003 | |
31/7/2020 06:45 | All going rather well Dr Adam M Hill, CEO of Oncimmune, said: "We are delighted to see the ECLS trial data published in the European Respiratory Journal, as it both expands the availability of these results in the wider pulmonology community and confirms through peer review the findings and clinical potential of EarlyCDT Lung. The ECLS trial data was presented on the Presidents podium at WCLC 2019 in Barcelona last year. This publication will unlock discussions with a number of health systems on implementation, many of whom have been looking forward to the validation that this much anticipated peer review brings. We and our partners will now work at speed with health authorities in the UK and further afield to roll out EarlyCDT Lung more widely, ahead of a fuller analysis of the survival benefit of EarlyCDT Lung." | waterloo01 | |
09/7/2020 20:30 | Simply, most people have have not heard of Oncimmune, but I am pretty sure the next 6-9 months will change that! | shearluc | |
09/7/2020 20:11 | I can't understand why this isn't on the move given the good news recently, seems to be well under the radar and not traded much?? | recut more | |
11/6/2020 07:15 | Here, @DDS_DocHoliday recently caught up with @OncimmuneECDT CEO Dr. Adam Hill. #ONC profiles the body's immune response to detect evidence of the body's natural response to cancer.In a fascinating interview Hill explains a little more...https://total | burtond1 | |
05/6/2020 06:49 | Decent number of director buys. | waterloo01 | |
28/5/2020 08:24 | Oncimmune Holdings PLC said Thursday that it has signed a new contract with Swiss pharmaceutical giant Roche Holding AG to profile autoantibodies in patient samples collected during cancer immunotherapy trials. The U.K. immunodiagnostics group said the contract, for the use of Oncimmune's SeroTag biomarker discovery platform to explore autoantibody profiles in patients that received cancer immunotherapy, will start immediately. Initial results are scheduled to be provided to Roche within three months, with project completion by November, Oncimmune said. Oncimmune Chief Executive Adam M Hill said this is the largest contract the company has signed to date and builds upon the collaborative work between the two companies in recent months. Write to Adria Calatayud at adria.calatayud@dowj (END) Dow Jones Newswires May 28, 2020 03:04 ET (07:04 GMT) | adrian j boris | |
21/5/2020 07:42 | Re foothill - On reflection a possibly more plain English interpretation should be a "toehold contract"!! | pugugly | |
21/5/2020 07:30 | "Foothill Contract" - Suggest early stage? Negotiations? The fact that it's signed is reassuring....would that stop another big pharma making enquiries? | shearluc | |
21/5/2020 06:51 | lol. Agreed never seen it sued but understand the intention. | waterloo01 | |
21/5/2020 06:34 | What the hell is a "foothil contract" New one on me - never come across before - Neither it appears has Google!! | pugugly | |
14/5/2020 11:40 | Can't find this could you explain please | pinkie | |
16/4/2020 15:04 | Nice to get in and plant a few seeds early. :) | mcrudden | |
16/4/2020 13:14 | Hello! good sign ;-) | smackeraim | |
16/4/2020 12:40 | Joined you in here appreciate the posts...gla | mcrudden | |
16/4/2020 12:34 | Blue again! | smackeraim | |
14/4/2020 20:14 | https://twitter.com/ | smackeraim | |
14/4/2020 20:14 | Yes I know mate. I know what they do lol | smackeraim |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions